Watchful waiting as a treatment option for localized prostate cancer in the PSA era.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Japanese Journal of Clinical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/JJCO/HYG011PMID 12604715
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Quality of life after radical prostatectomy or watchful waiting.

  2002cited by this paper
• A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer.

  2002cited by this paper
• Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.

  2002influential reference
• Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men.

  2002cited by this paper
• [The epidemiology of prostate cancer--recent trends in prostate cancer incidence and mortality].

  2001cited by this paper
• Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors?

  2001cited by this paper
• Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer.

  2001cited by this paper
• Long-term survival in a Swedish population-based cohort of men with prostate cancer.

  2000cited by this paper
• Clinical Significance of Nonpalpable Prostate Cancer with Favorable Biopsy Features in Japanese Men

  2000cited by this paper
• Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer.

  1999cited by this paper
• Estimates of the worldwide incidence of 25 major cancers in 1990

  1999influential reference
• Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.

  1999cited by this paper
• Effects of cachexia due to cancer on whole body and skeletal muscle protein turnover

  1998cited by this paper
• Screening for prostate cancer: estimating the magnitude of overdetection.

  1998cited by this paper
• Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer

  1998cited by this paper
• Therapeutic Dilemmas in Prostate Cancer: Justification for Watchful Waiting

  1998cited by this paper
• Urinary symptoms, potency, and quality of life in patients with localized prostate cancer followed up with deferred treatment.

  1998cited by this paper
• Watchful waiting or watchful progression?

  1998cited by this paper
• Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy.

  1998cited by this paper
• The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program.

  1998cited by this paper
• Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden.

  1997cited by this paper
• The results of prostate carcinoma screening in the U. S. As reflected in the surveillance, epidemiology, and end results program

  1997influential reference
• An adjustment to the 1997 estimate for new prostate cancer cases

  1997cited by this paper
• Prospective evaluation of men with stage T1C adenocarcinoma of the prostate.

  1997cited by this paper
• Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens--a different view.

  1997cited by this paper
• Prostate carcinoma incidence and patient mortality

  1997cited by this paper
• The definition and preoperative prediction of clinically insignificant prostate cancer.

  1996cited by this paper
• Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies.

  1996cited by this paper
• Core cancer length in ultrasound-guided systematic sextant biopsies: a preoperative evaluation of prostate cancer volume.

  1995cited by this paper
• Results of conservative management of clinically localized prostate cancer.

  1994cited by this paper
• The frequency of latent prostatic carcinoma in young males: the Japanese experience.

  1994cited by this paper
• The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer.

  1994cited by this paper
• Observations on the doubling time of prostate cancer. The use of serial prostate‐specific antigen in patients with untreated disease as a measure of increasing cancer volume

  1993cited by this paper
• Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.

  1992cited by this paper
• Low-grade, latent prostate cancer volume: predictor of clinical cancer incidence?

  1991cited by this paper
• Early detection for prostate cancer?

  1991cited by this paper
• Re: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate.

  1990cited by this paper
• Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients.

  1989cited by this paper
• Person-years of life lost due to cancer in the United States, 1970 and 1984.

  1989cited by this paper
• Trends in frequency of latent prostate carcinoma in Japan from 1965-1979 to 1982-1986.

  1988cited by this paper

• Treatment outcomes of 125I low-dose-rate brachytherapy vs radical prostatectomy for patients with intermediate-risk prostate cancer

  2020cites this paper
• Prevalence of Erectile Dysfunction in Male Cancer: a Systematic Review and Meta-Analysis of Cross-Sectional Studies

  2020cites this paper
• Prevalence of erectile dysfunction in male survivors of cancer: a systematic review and meta-analysis of cross-sectional studies

  2020cites this paper
• Radical prostatectomy versus deferred treatment for localised prostate cancer.

  2020cites this paper
• 125I low-dose-rate prostate brachytherapy and radical prostatectomy in patients with prostate cancer.

  2019cites this paper
• Role and clinical significance of miRNA-381 in prostate cancer

  2017influential citation
• miR-30c suppresses prostate cancer survival by targeting the ASF/SF2 splicing factor oncoprotein

  2017cites this paper
• BCL9, a coactivator for Wnt/β-catenin transcription, is targeted by miR-30c and is associated with prostate cancer progression

  2016cites this paper
• Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.

  2013cites this paper
• Prostate cancer in the senior men from rural areas in east district of China: contemporary management and 5-year outcomes at multi-institutional collaboration.

  2012cites this paper
• Association of Tissue Promoter Methylation Levels of APC, RASSF1A, CYP26A1, and TBX15 with Prostate Cancer Progression

  2012cites this paper
• Expression of CD147 is associated with prostate cancer progression

  2012cites this paper
• Correlation Analysis of JAK-STAT Pathway Components on Prognosis of Patients with Prostate Cancer

  2011cites this paper
• Lentivirus-mediated RNAi knockdown of prostate-specific membrane antigen suppresses growth, reduces migration ability and the invasiveness of prostate cancer cells

  2011cites this paper
• Radical prostatectomy versus watchful waiting for prostate cancer.

  2010cites this paper
• What Is the “True” Incidence of Active Surveillance and Brachytherapy Candidates in Men Undergoing Robot-Assisted Radical Prostatectomy?

  2010cites this paper
• Cancer and sexual problems.

  2010cites this paper
• Increased expression of elongation factor-1α is significantly correlated with poor prognosis of human prostate cancer

  2010cites this paper
• CD147 Expression Indicates Unfavourable Prognosis in Prostate Cancer

  2009influential citation
• CD147, MMP-1, MMP-2 and MMP-9 Protein Expression as Significant Prognostic Factors in Human Prostate Cancer

  2008cites this paper
• Evidence‐based Clinical Practice Guidelines for Prostate Cancer (Summary – JUA 2006 Edition)

  2008cites this paper
• Active surveillance for favorable-risk prostate cancer: who, how and why?

  2007cites this paper
• Potential predictive factors of positive prostate biopsy in the Japanese population

  2007cites this paper
• Active surveillance versus radical treatment for favorable-risk localized prostate cancer

  2006cites this paper
• Trends in in-patient Hospital Utilization and Surgical Procedures for Breast, Prostate, Lung and Colorectal Cancers in Canada

  2005cites this paper
• CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: a new prognostic indicator?

  2004cites this paper
• Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE.

  2003cites this paper
• Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapy.

  2003cites this paper
• I low ‐ dose ‐ rate prostate brachytherapy and radical prostatectomy in patients with prostate cancer

  year unknowncites this paper